Phase 2 Trials Begin Dosing Patients with SHR0302, Reistone’s Investigational JAK1 Inhibitor

Phase 2 Trials Begin Dosing Patients with SHR0302, Reistone’s Investigational JAK1 Inhibitor
The first patients with ulcerative colitis (UC) and Crohn's disease (CD) have been dosed in two Phase 2 trials assessing the effects of SHR0302, Reistone Biopharma's investigational drug for the treatment of patients with inflammatory bowel disease (IBD). SHR0302 is a potent selective inhibitor of Janus kinase 1 (JAK1), one of the proteins from the JAKs family that controls inflammation in response to cytokines, which are molecules released by immune cells that play a major role in inflammation and autoimmunity. JAK inhibitors are able to dampen the body's inflammatory and autoimmune response by interfering with the signaling cascade controlled by JAKs. Unlike other types of JAK inhibitors currently available, SHR0302 only inhibits the activity of JAK1, leaving other JAK proteins unscathed. For this reason, selective JAK inhibitors such as SHR0302 may be a safer option for patients, as their use minimizes the occurrence of undesirable side effects arising from all-around inhibition of JAK proteins. The safety and efficacy of SHR0302 in patients with moderate to severe UC and CD is currently being assessed in two multi-center, randomized, double-blind, placebo-controlled, Phase 2 trials: RSJ10101 (NCT03675477) and RSJ10201 (NCT03677648). "We are excited to advance our selective JAK1 inhibitor into our global Phase 2 trials for UC and CD. Reistone is committed to bringing this innovative drug developed in China to the world," Min Irwin, CEO and co-founder of Reistone, said in a press release. RSJ10101 is a 16-week trial, in which UC patients who complete the initial eight-week phase of treatment will have the chance to continue treatment for another eight weeks during the blinded extension phase of the study. In the first phase, UC patients will be ra
Subscribe or to access all post and page content.